Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00233662
Status:
COMPLETED
Last Update Posted:
2023-08-23
First Post:
2005-10-04
Brief Title:
Safety and Tolerability of Repeat Courses of IM Alefacept
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
An Open-Label Multicenter Study to Evaluate the Safety and Tolerability of Repeat Courses of Intramuscular Administration of Alefacept LFA-3IgG1 Fusion Protein in Patients With Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether repeat courses of alefacept administered intramuscularly are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None